Proteins and Peptides

12 Sep 2007 Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
12 Sep 2007 Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11 Sep 2007 Neose Announces Initiation of Phase II Renal Trial of NE-180
11 Sep 2007 Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
11 Sep 2007 Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
11 Sep 2007 First Ever Therapy Targets Optic Nerve Head for Glaucoma
07 Sep 2007 FDA has approved Zealand Pharma's Investigative New Drug application
07 Sep 2007 Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
06 Sep 2007 Pieris validates the use of Anticalins(R) as ophthalmologic biotherapeutics
05 Sep 2007 ThromboGenics Announces Successful Completion of Technology Transfer to
04 Sep 2007 GTC obtains FDA fast track designation for Atryn(R) and permission to submit a rolling BLA
04 Sep 2007 Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
04 Sep 2007 Astellas Announces the Extension of US Regulatory Review for the sNDA of MYCAMINE
01 Sep 2007 BioDiem starts 4 new Monash studies with eye drug BDM-E
01 Sep 2007 Somatuline(R) Depot receives marketing approval in the United States
01 Sep 2007 MediGene: European Approval Procedure for the Six-Months Dosage of Cancer Drug Eligard(R) Successfully Completed
31 Aug 2007 New formulation of multiple sclerosis treatment Rebif (R) approved in European Union
31 Aug 2007 Paion's partner Forest terminates co-development on Desmoteplase
31 Aug 2007 Pharming Presents Positive Results From European Phase III Trial Of Rhucin(R)
30 Aug 2007 King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
30 Aug 2007 Orexo's treatment for incontinence/nocturia entering Phase I
29 Aug 2007 OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Thrombin Stand Alone, EVITHROM* Thrombin, Topical (Human), with General Hemostasis in Surgery Indication
29 Aug 2007 Human genome sciences completes enrollment of first Phase 3 Albuferon(R) trial ahead of schedule
29 Aug 2007 Curis Updates Research on Hedgehog Agonist Protein Program for Cardiovascular Disease Indications
29 Aug 2007 Ambrilia Completes Patient Recruitment for the Phase 3 Pivotal Clinical Trial of its Prolonged Release Formulation of Octreotide

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top